Literature DB >> 21536930

Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer.

Hiroyuki Okudaira1, Naoto Shikano, Ryuichi Nishii, Tohru Miyagi, Mitsuyoshi Yoshimoto, Masato Kobayashi, Kazuyo Ohe, Takeo Nakanishi, Ikumi Tamai, Mikio Namiki, Keiichi Kawai.   

Abstract

UNLABELLED: Trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) is an amino acid PET tracer that has shown promise for visualizing prostate cancer. Therefore, we aimed to clarify the anti-(18)F-FACBC transport mechanism in prostate cancer cells. We also studied the fate of anti-(18)F-FACBC after it is transported into cells.
METHODS: For convenience, because of their longer half-lives, (14)C compounds were used instead of (18)F-labeled tracers. Trans-1-amino-3-fluoro-1-(14)C-cyclobutanecarboxylic acid ((14)C-FACBC) uptake was examined in human prostate cancer DU145 cells with the following substrates of amino acid transporters: α-(methylamino) isobutyric acid (a system A-specific substrate) and 2-amino-2-norbornanecarboxylic acid (a system L-specific substrate). The messenger RNA expression of amino acid transporters in human prostate cancer specimens was analyzed by complementary DNA microarray and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Gene expression in DU145 cells was analyzed by qRT-PCR. We also examined the knockdown effect of the amino acid transporters system ASC transporter 2 (ASCT2) and sodium-coupled neutral amino acid transporter 2 (SNAT2) on (14)C-FACBC uptake. In addition, the possibility of (14)C-FACBC incorporation into proteins was examined.
RESULTS: (14)C-FACBC uptake by DU145 cells was markedly decreased to approximately 20% in the absence of Na(+), compared with that in its presence, indicating that Na(+)-dependent transporters are mainly responsible for the uptake of this tracer. Moreover, 2-amino-2-norbornanecarboxylic acid inhibited the transport of (14)C-FACBC to the basal level in Na(+)-free buffer. In contrast, α-(methylamino) isobutyric acid did not inhibit (14)C-FACBC accumulation in DU145 cells. Human prostate tumor specimens and DU145 cells had similar messenger RNA expression patterns of amino acid transporter genes. Although SNAT2 and ASCT2 are 2 major amino acid transporters expressed in prostate tumor tissues and DU145 cells, ASCT2 knockdown using small interfering RNA was more effective in lowering (14)C-FACBC transport than SNAT2. Almost all intracellular (14)C-FACBC was recovered from the nonprotein fraction.
CONCLUSION: ASCT2, which is a Na(+)-dependent amino acid transporter, and to a lesser extent Na(+)-independent transporters play a role in the uptake of (14)C-FACBC by DU145 cells. Among the Na(+)-independent transporters, system L transporters are also involved in the transport of (14)C-FACBC. Moreover, (14)C-FACBC is not incorporated into proteins in cells. These findings suggest a possible mechanism of anti-(18)F-FACBC PET for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536930     DOI: 10.2967/jnumed.110.086074

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  44 in total

Review 1.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.

Authors:  Mark A White; Chenchu Lin; Kimal Rajapakshe; Jianrong Dong; Yan Shi; Efrosini Tsouko; Ratna Mukhopadhyay; Diana Jasso; Wajahat Dawood; Cristian Coarfa; Daniel E Frigo
Journal:  Mol Cancer Res       Date:  2017-05-15       Impact factor: 5.852

Review 3.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 4.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Authors:  Ronnie C Mease; Catherine A Foss; Martin G Pomper
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

5.  Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

Authors:  Chung Yao Yu; Bhushan Desai; Lingyun Ji; Susan Groshen; Hossein Jadvar
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

Review 6.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

7.  Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.

Authors:  Oladunni O Akin-Akintayo; Ashesh B Jani; Oluwaseun Odewole; Funmilayo I Tade; Peter T Nieh; Viraj A Master; Leah M Bellamy; Raghuveer K Halkar; Chao Zhang; Zhengjia Chen; Mark M Goodman; David M Schuster
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

8.  Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.

Authors:  Young Joo Jeon; Sihem Khelifa; Boris Ratnikov; David A Scott; Yongmei Feng; Fabio Parisi; Chelsea Ruller; Eric Lau; Hyungsoo Kim; Laurence M Brill; Tingting Jiang; David L Rimm; Robert D Cardiff; Gordon B Mills; Jeffrey W Smith; Andrei L Osterman; Yuval Kluger; Ze'ev A Ronai
Journal:  Cancer Cell       Date:  2015-03-09       Impact factor: 31.743

9.  Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts.

Authors:  F I Tade; W G Wiles; G Lu; B Bilir; O Akin-Akintayo; J S Lee; D Patil; W Yu; C Ormenisan Gherasim; B Fei; C S Moreno; A O Osunkoya; E J Teoh; S Oka; H Okudaira; M M Goodman; D M Schuster
Journal:  Amino Acids       Date:  2018-06-15       Impact factor: 3.520

Review 10.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.